Studies exploring the association between vutrisiran and all-cause mortality and the prognostic information gleaned from serum transthyretin (sTTR) levels in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), using data from the HELIOS-B and ATTRibute-CM trials respectively, were published in a JACC Special Focus Issue on cardiac amyloidosis.

The dual GIP/GLP-1 receptor agonist tirzepatide is effective in improving cardiometabolic abnormalities and resolving metabolic syndrome (MetS) in patients with type 2 diabetes (T2D) compared to placebo or standard antihyperglycemic therapies according to a new pooled analysis published in JACC.

Cardiovascular magnetic resonance (CMR) imaging was able to detect longer myocardial T₂, higher extracellular volume (ECV) fraction and worse myocardial dynamics, including impaired strain, before significant decline in left ventricular (LV) systolic function in carriers of LMNA (Lamin) dilated cardiomyopathy (DCM). Furthermore, the CMR-derived biomarkers of fibrosis (based on ECV) and strain are prognostic for major adverse cardiovascular events (MACE) during the disease's progression, according to a new study published in JACC: Cardiovascular Imaging.

Conduction system pacing (CSP) was noninferior to biventricular pacing (BiVP) in achieving clinical and echocardiographic response, suggesting that CSP could be an alternative to BiVP, according to results from the CONSYST-CRT trial published in JACC: Clinical Electrophysiology.

Withdrawal of other heart failure treatment while maintaining carvedilol as a single therapy did not worsen left ventricular (LV) function compared to usual treatment at 52 weeks in patients with heart failure with improved ejection fraction (HFimpEF), according to a brief report on the CATHEDRAL-HF trial published in JACC: Heart Failure.